{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:56:23Z","timestamp":1784249783839,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01KX2121"],"award-info":[{"award-number":["01KX2121"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The majority of patients recovers from severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) coronavirus disease 2019 (COVID-19) without obvious sequelae, but a significant proportion suffers long-term consequences which have been termed post COVID syndrome (PCS). Despite a wide range of considerations on treatment options in PCS and a significant number of trials initiated, only very few results from randomized controlled trials are currently available. In conclusion, there is an evident medical need to identify treatments for patients with PCS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The primary objective of the platform trial RAPID is to assess the impact of different PCS treatments on the overall physical function of patients. Designed as a master protocol, RAPID contains all information that is generic to this adaptive platform trial. Current and future study treatments are specified in intervention-specific appendices (ISA). The first ISA, RAPID_REVIVE is presented in this manuscript. General sections of the master protocol are named as such.<\/jats:p>\n            <jats:p>RAPID_REVIVE is a double-blind, placebo-controlled, phase II clinical trial evaluating antiviral PCS treatment with vidofludimus calcium (IMU-838). Patients are randomized at a 1:1 ratio to 45\u00a0mg\/day vidofludimus calcium (22.5\u00a0mg for the first 7\u00a0days) or placebo during an initialization phase and thereafter using a response-adaptive randomization procedure. The trial includes a screening period of 7\u00a0days, a double-blind treatment period of 56\u00a0days and a follow-up period of 28\u00a0days. The primary outcome is the intra-patient change in physical function measured by the Short Form-36 Physical Function (SF-36-PF) from baseline to day 56. Secondary endpoints include mental and physical health, intensity of fatigue, severity of mental disorder symptoms, and cognitive function.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>PCS is a major problem for global health care and the identification of treatment options is urgently needed. Currently, PCS patients are in a situation without evidence-based treatment options, and quality of life, and often mental health are significantly impaired. The purpose of RAPID is to establish an adaptive platform trial protocol which will concert and quicken clinical trials to evaluate the efficacy and safety of different potential treatments for PCS with the aim to expand the very limited evidence base for the treatment of PCS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>EU Clinical Trials Register (CTIS) ID: 2024\u2013511628-16\u201300 (RAPID_REVIVE). Registered on 18.03.2024.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13063-025-09008-0","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T22:12:58Z","timestamp":1755641578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Randomized adaptive assessment of post COVID syndrome treatments (RAPID): a study protocol for a multicenter, randomized, controlled adaptive platform trial of treatment options for Post Covid Syndrome (PCS) on patients physical function including the first intervention specific appendix RAPID_REVIVE (reducing inflammatory activity in patients with PCS)"],"prefix":"10.1186","volume":"26","author":[{"given":"Lisa","family":"Weipert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph G.","family":"Telgmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Anton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Asendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Chaplinskaja-Sobol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Ciesek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Drescher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Friede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Groth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Han\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Illig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Krefting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Muehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Nauck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Schaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Cathrin","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Sawitzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Tostmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"9008_CR1","doi-asserted-by":"publisher","first-page":"10902","DOI":"10.1038\/s41598-021-90351-y","volume":"11","author":"T Chen","year":"2021","unstructured":"Chen T, Song J, Liu H, Zheng H, Chen C. Positive Epstein-Barr virus detection in coronavirus disease 2019 (COVID-19) patients. Sci Rep. 2021;11:10902. https:\/\/doi.org\/10.1038\/s41598-021-90351-y.","journal-title":"Sci Rep"},{"key":"9008_CR2","doi-asserted-by":"publisher","first-page":"100122","DOI":"10.1016\/j.lanepe.2021.100122","volume":"6","author":"M Augustin","year":"2021","unstructured":"Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur. 2021;6: 100122. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100122.","journal-title":"Lancet Reg Health Eur"},{"key":"9008_CR3","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41591-021-01283-z","volume":"27","author":"A Nalbandian","year":"2021","unstructured":"Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601\u201315. https:\/\/doi.org\/10.1038\/s41591-021-01283-z.","journal-title":"Nat Med"},{"key":"9008_CR4","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41590-021-01104-y","volume":"23","author":"S Mehandru","year":"2022","unstructured":"Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022;23:194\u2013202. https:\/\/doi.org\/10.1038\/s41590-021-01104-y.","journal-title":"Nat Immunol"},{"key":"9008_CR5","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41591-021-01292-y","volume":"27","author":"CH Sudre","year":"2021","unstructured":"Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27:626\u201331. https:\/\/doi.org\/10.1038\/s41591-021-01292-y.","journal-title":"Nat Med"},{"key":"9008_CR6","unstructured":"Rajan S, Khunti K, Alwan N, Steves C, MacDermott N, Morsella A, et al. In the wake of the pandemic: Preparing for Long COVID. Copenhagen (Denmark); 2021."},{"key":"9008_CR7","doi-asserted-by":"publisher","first-page":"e933446","DOI":"10.12659\/MSM.933446","volume":"27","author":"DV Parums","year":"2021","unstructured":"Parums DV. Editorial: Long COVID, or post-COVID syndrome, and the global impact on health care. Med Sci Monit. 2021;27: e933446. https:\/\/doi.org\/10.12659\/MSM.933446.","journal-title":"Med Sci Monit"},{"key":"9008_CR8","doi-asserted-by":"publisher","unstructured":"Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203:631\u20137. https:\/\/doi.org\/10.1002\/path.1570.","DOI":"10.1002\/path.1570"},{"key":"9008_CR9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01948-2020","author":"M Chen","year":"2020","unstructured":"Chen M, Shen W, Rowan NR, Kulaga H, Hillel A, Ramanathan M, Lane AP. Elevated ACE-2 expression in the olfactory neuroepithelium: implications for anosmia and upper respiratory SARS-CoV-2 entry and replication. Eur Respir J. 2020. https:\/\/doi.org\/10.1183\/13993003.01948-2020.","journal-title":"Eur Respir J"},{"key":"9008_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jama.2020.12603","volume":"324","author":"A Carf\u00ec","year":"2020","unstructured":"Carf\u00ec A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603\u20135. https:\/\/doi.org\/10.1001\/jama.2020.12603.","journal-title":"JAMA"},{"key":"9008_CR11","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(21)01755-4","volume":"398","author":"L Huang","year":"2021","unstructured":"Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398:747\u201358. https:\/\/doi.org\/10.1016\/S0140-6736(21)01755-4.","journal-title":"Lancet"},{"key":"9008_CR12","doi-asserted-by":"publisher","first-page":"16144","DOI":"10.1038\/s41598-021-95565-8","volume":"11","author":"S Lopez-Leon","year":"2021","unstructured":"Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, Villapol S. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11:16144. https:\/\/doi.org\/10.1038\/s41598-021-95565-8.","journal-title":"Sci Rep"},{"key":"9008_CR13","doi-asserted-by":"publisher","first-page":"101019","DOI":"10.1016\/j.eclinm.2021.101019","volume":"38","author":"HE Davis","year":"2021","unstructured":"Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re\u2019em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38: 101019. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101019.","journal-title":"EClinicalMedicine"},{"key":"9008_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","volume":"21","author":"HE Davis","year":"2023","unstructured":"Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133\u201346. https:\/\/doi.org\/10.1038\/s41579-022-00846-2.","journal-title":"Nat Rev Microbiol"},{"key":"9008_CR15","doi-asserted-by":"publisher","unstructured":"Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens de Noordhout C, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022;54:1473\u201387. https:\/\/doi.org\/10.1080\/07853890.2022.2076901.","DOI":"10.1080\/07853890.2022.2076901"},{"key":"9008_CR16","doi-asserted-by":"publisher","first-page":"746021","DOI":"10.3389\/fimmu.2021.746021","volume":"12","author":"BK Patterson","year":"2021","unstructured":"Patterson BK, Francisco EB, Yogendra R, Long E, Pise A, Rodrigues H, et al. Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infection. Front Immunol. 2021;12: 746021. https:\/\/doi.org\/10.3389\/fimmu.2021.746021.","journal-title":"Front Immunol"},{"key":"9008_CR17","doi-asserted-by":"publisher","DOI":"10.1101\/2020.11.03.367391","author":"C Gaebler","year":"2021","unstructured":"Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. bioRxiv. 2021. https:\/\/doi.org\/10.1101\/2020.11.03.367391.","journal-title":"bioRxiv"},{"key":"9008_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1053\/j.gastro.2022.04.037","volume":"163","author":"A Zollner","year":"2022","unstructured":"Zollner A, Koch R, Jukic A, Pfister A, Meyer M, R\u00f6ssler A, et al. Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology. 2022;163:495-506.e8. https:\/\/doi.org\/10.1053\/j.gastro.2022.04.037.","journal-title":"Gastroenterology"},{"key":"9008_CR19","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/jamainternmed.2023.0743","volume":"183","author":"Y Xie","year":"2023","unstructured":"Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern Med. 2023;183:554\u201364. https:\/\/doi.org\/10.1001\/jamainternmed.2023.0743.","journal-title":"JAMA Intern Med"},{"key":"9008_CR20","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s40121-022-00690-0","volume":"11","author":"MJGT Vehreschild","year":"2022","unstructured":"Vehreschild MJGT, Atanasov P, Yurko K, Oancea C, Popov G, Smesnoi V, et al. Safety and efficacy of Vidofludimus calcium in patients hospitalized with COVID-19: a double-blind, randomized, placebo-controlled, phase 2 trial. Infect Dis Ther. 2022;11:2159\u201376. https:\/\/doi.org\/10.1007\/s40121-022-00690-0.","journal-title":"Infect Dis Ther"},{"key":"9008_CR21","doi-asserted-by":"publisher","first-page":"394","DOI":"10.14218\/ERHM.2022.00045","volume":"000","author":"LN Geng","year":"2023","unstructured":"Geng LN, Bonilla HF, Shafer RW, Miglis MG, Yang PC. The use of Nirmatrelvir-ritonavir in a case of breakthrough long COVID. Explor Res Hypothes Med. 2023;000:394\u20136. https:\/\/doi.org\/10.14218\/ERHM.2022.00045.","journal-title":"Explor Res Hypothes Med"},{"key":"9008_CR22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163669","author":"MJ Peluso","year":"2023","unstructured":"Peluso MJ, Deveau T-M, Munter SE, Ryder D, Buck A, Beck-Engeser G, et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest. 2023. https:\/\/doi.org\/10.1172\/JCI163669.","journal-title":"J Clin Invest"},{"key":"9008_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10060763","author":"JE Gold","year":"2021","unstructured":"Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens. 2021. https:\/\/doi.org\/10.3390\/pathogens10060763.","journal-title":"Pathogens"},{"key":"9008_CR24","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1186\/s13054-020-03384-6","volume":"24","author":"GF Lehner","year":"2020","unstructured":"Lehner GF, Klein SJ, Zoller H, Peer A, Bellmann R, Joannidis M. Correlation of interleukin-6 with Epstein-Barr virus levels in COVID-19. Crit Care. 2020;24:657. https:\/\/doi.org\/10.1186\/s13054-020-03384-6.","journal-title":"Crit Care"},{"key":"9008_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/all.15471","volume":"78","author":"J Rohrhofer","year":"2023","unstructured":"Rohrhofer J, Graninger M, Lettenmaier L, Schweighardt J, Gentile SA, Koidl L, et al. Association between Epstein-Barr-virus reactivation and development of long-COVID fatigue. Allergy. 2023;78:297\u20139. https:\/\/doi.org\/10.1111\/all.15471.","journal-title":"Allergy"},{"key":"9008_CR26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ijid.2020.12.051","volume":"104","author":"S Paolucci","year":"2021","unstructured":"Paolucci S, Cassaniti I, Novazzi F, Fiorina L, Piralla A, Comolli G, et al. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. Int J Infect Dis. 2021;104:315\u20139. https:\/\/doi.org\/10.1016\/j.ijid.2020.12.051.","journal-title":"Int J Infect Dis"},{"key":"9008_CR27","doi-asserted-by":"publisher","first-page":"102129","DOI":"10.1016\/j.msard.2020.102129","volume":"43","author":"A Muehler","year":"2020","unstructured":"Muehler A, Peelen E, Kohlhof H, Gr\u00f6ppel M, Vitt D. Vidofludimus calcium, a next generation DHODH inhibitor for the treatment of relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2020;43: 102129. https:\/\/doi.org\/10.1016\/j.msard.2020.102129.","journal-title":"Mult Scler Relat Disord"},{"key":"9008_CR28","doi-asserted-by":"publisher","unstructured":"Hahn F, Wangen C, H\u00e4ge S, Peter AS, Dobler G, Hurst B, et al. IMU-838, a developmental DHODH inhibitor in phase II for autoimmune disease, shows anti-SARS-CoV-2 and broad-spectrum antiviral efficacy in vitro. Viruses. 2020. https:\/\/doi.org\/10.3390\/v12121394.","DOI":"10.3390\/v12121394"},{"key":"9008_CR29","unstructured":"Bell DS. The doctor's guide to chronic fatigue syndrome : understanding, treating, and living with CFIDS \/ David S. Bell. Reading, Mass.: Addison-Wesley Pub. Co; 1994."},{"key":"9008_CR30","unstructured":"sarram. 14.6. 2020_09_HMA_CTFG_Contraception_guidance_Version_1.2 draft."},{"key":"9008_CR31","doi-asserted-by":"publisher","unstructured":"Shahid A, Wilkinson K, Marcu S, Shapiro CM. Fatigue Severity Scale (FSS) 2011: Springer New York. https:\/\/doi.org\/10.1007\/978-1-4419-9893-4_35.","DOI":"10.1007\/978-1-4419-9893-4_35"},{"key":"9008_CR32","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","volume":"166","author":"RL Spitzer","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JBW, L\u00f6we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092\u20137. https:\/\/doi.org\/10.1001\/archinte.166.10.1092.","journal-title":"Arch Intern Med"},{"key":"9008_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jad.2008.06.026","volume":"114","author":"K Kroenke","year":"2009","unstructured":"Kroenke K, Strine TW, Spitzer RL, Williams JBW, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114:163\u201373. https:\/\/doi.org\/10.1016\/j.jad.2008.06.026.","journal-title":"J Affect Disord"},{"key":"9008_CR34","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/00006842-200203000-00008","volume":"64","author":"K Kroenke","year":"2002","unstructured":"Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002;64:258\u201366. https:\/\/doi.org\/10.1097\/00006842-200203000-00008.","journal-title":"Psychosom Med"},{"key":"9008_CR35","doi-asserted-by":"publisher","DOI":"10.1026\/0012-1924.50.4.171","author":"K Gr\u00e4fe","year":"2004","unstructured":"Gr\u00e4fe K, Zipfel S, Herzog W, L\u00f6we B. Screening psychischer St\u00f6rungen mit dem\u201cGesundheitsfragebogen f\u00fcr Patienten (PHQ-D). Diagnostica. 2004. https:\/\/doi.org\/10.1026\/0012-1924.50.4.171.","journal-title":"Diagnostica"},{"key":"9008_CR36","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/crj.12002","volume":"6","author":"J Vestbo","year":"2012","unstructured":"Vestbo J, Hurd SS, Rodriguez-Roisin R. The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD)\u2013why and what? Clin Respir J. 2012;6:208\u201314. https:\/\/doi.org\/10.1111\/crj.12002.","journal-title":"Clin Respir J"},{"key":"9008_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics8030066","author":"J Cotler","year":"2018","unstructured":"Cotler J, Holtzman C, Dudun C, Jason LA. A brief questionnaire to assess post-exertional malaise. Diagnostics (Basel). 2018. https:\/\/doi.org\/10.3390\/diagnostics8030066.","journal-title":"Diagnostics (Basel)"},{"key":"9008_CR38","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695\u20139. https:\/\/doi.org\/10.1111\/j.1532-5415.2005.53221.x.","journal-title":"J Am Geriatr Soc"},{"key":"9008_CR39","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/21641846.2018.1512836","volume":"6","author":"M Roma","year":"2018","unstructured":"Roma M, Marden CL, Rowe PC. Passive standing tests for the office diagnosis of postural tachycardia syndrome: new methodological considerations. Fatigue Biomed Health Behav. 2018;6:179\u201392. https:\/\/doi.org\/10.1080\/21641846.2018.1512836.","journal-title":"Fatigue Biomed Health Behav"},{"key":"9008_CR40","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0378-3758(99)00198-6","volume":"87","author":"VF Melfi","year":"2000","unstructured":"Melfi VF, Page C. Estimation after adaptive allocation. J Stat Plann Inference. 2000;87:353\u201363. https:\/\/doi.org\/10.1016\/S0378-3758(99)00198-6.","journal-title":"J Stat Plann Inference"},{"key":"9008_CR41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/0962280219833079","volume":"29","author":"C R\u00f6ver","year":"2020","unstructured":"R\u00f6ver C, Friede T. Dynamically borrowing strength from another study through shrinkage estimation. Stat Methods Med Res. 2020;29:293\u2013308. https:\/\/doi.org\/10.1177\/0962280219833079.","journal-title":"Stat Methods Med Res"},{"key":"9008_CR42","doi-asserted-by":"publisher","first-page":"106154","DOI":"10.1016\/j.cct.2020.106154","volume":"98","author":"T M\u00fctze","year":"2020","unstructured":"M\u00fctze T, Friede T. Data monitoring committees for clinical trials evaluating treatments of COVID-19. Contemp Clin Trials. 2020;98: 106154. https:\/\/doi.org\/10.1016\/j.cct.2020.106154.","journal-title":"Contemp Clin Trials"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09008-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09008-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09008-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T10:02:02Z","timestamp":1755684122000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09008-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9008"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09008-0","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This clinical trial was designed, shall be implemented and reported in accordance with ICH GCP, with applicable regulations (including Regulation (EU) No. 536\/2014), and with the ethical principles laid down in the Declaration of Helsinki.This clinical trial protocol has been approved via CTIS by Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM) and the central ethics committee of the Trial on 31. May 2024. Prior to randomization, written informed consent will be obtained from the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"The consent forms (2 versions depending on whether an MRI is desired by the patient or not  and the consent for secondary use) and other related documentation will be given to  participants (Additional files 1, 2 and 3).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"OAC reports grants or contracts from BMBF, Cidara, DZIF, EU-DG RTD, F2G, Gilead,  MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; Consulting fees from Abbvie,  AiCuris, Basilea, Biocon, Boston Strategic Partners, Cidara, Seqirus, Gilead, GSK, IQVIA,  Janssen, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Mundipharma,  Noxxon, Octapharma, Pardes, Partner Therapeutics, Pfizer, PSI, Scynexis, Seres, Shionogi,  The Prime Meridian Group, Elion Therapeutics, Menarini, Melinta; Speaker and lecture  honoraria from Abbott, Abbvie, Akademie f\u00fcr Infektionsmedizin, Al-Jazeera  Pharmaceuticals\/Hikma, amedes, AstraZeneca, Deutscher \u00c4rzteverlag, Gilead, GSK, Grupo  Biotoscana\/United Medical\/Knight, Ipsen Pharma, Medscape\/WebMD, MedUpdate, MSD,  Moderna, Mundipharma, Noscendo, Paul-Martini-Stiftung, Pfizer, Sandoz, Seqirus, Shionogi,  streamedup!, Touch Independent, Vitis; Payment for expert testimony Cidara; Participation  on a DRC, DSMB, DMC, Advisory Board for Cidara, IQVIA, Janssen, MedPace, PSI,  Pulmocide, Vedanta Biosciences, AstraZeneca, Melinta.  MV reports grants or contracts from MSD, Heel, BioNTech, Roche, SD Biosensor, Tillotts;  Consulting fees from Ferring, Tillotts, Bioaster; Speaker and lecture honoraria from  Akademie f\u00fcr \u00c4rztliche Fort- und Weiterbildung, Akadmie f\u00fcr Infektionsmedizin, Astra  Zeneca, bioMerieux, DGI, EUMEDICA, European Society of Neurogastroenterology,  Ferring, FomF GmbH, F\u00f6rderkreis Malteser, Frankfurter B\u00fcrger Universit\u00e4t, GILEAD, GSK,  Helios Kliniken, Hessisches Landessozialgericht, Janssen Cilag GmbH, J\u00f6rg Eikerle  Beratung, Klinikum Leverkusen, Lahn-Dill Kliniken, Landes\u00e4rztekammer Hessen, LMU  Kliniken, Med. Gesellschaft Bad Homburg, MSD, Pfizer, St. Vincent Hospital, Tillotts.  The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"297"}}